SCD and cancer: On the one hand, in non-cancer tissues, such as liver, muscle, and adipose, NR4A1 can alter the expression levels of fatty acid key enzymes ACC, SCD1, CPT1A, as well as transporters CD36, adiponectin receptor 2 (ADIPOR2), and Caveolin 3 (CAV3) by regulating LKB1-AMPK classic signaling pathway and its downstream SREBP1c and FAS.